CheMastery EIS

The global chemical industry is worth more than $6 trillion annually and serves almost every sector – from medicines and manufactured goods to agriculture, food and drink.

However, much of modern chemical R&D still depends on manual execution, inconsistent processes and fragmented data, even though the outputs need to be reliable, repeatable and scalable. Before a compound can be manufactured at scale, chemists may spend years designing reactions, testing solvents, optimising yields, purifying samples and characterising results.

As a result, skilled chemists spend more than 65% of their time on repetitive lab work.

Moreover, results may be difficult to reproduce due to fragmented workflows, lack of standardised procedures and data scattered across instruments and notebooks, creating a disconnect between the discovery and commercial manufacturing phases.

CheMastery has developed an integrated hardware-software platform that standardises experimentation, captures structured data and automates up to 90% of laboratory R&D processes.

The system combines AI-enabled modular robotics, chemistry execution software, and ‘Design of Experiments’ tools (DoE is an efficient, statistical approach used to test how given factors will influence outcomes).

The Company operates a Robot-As-a-Service (RaaS) model: leasing the robotic hardware and cloud-based software through a subscription. This makes it easier and more affordable for laboratories to transition from their existing R&D processes.

The global lab automation industry is a large and growing market, expected to reach c.$9 billion by 2030 – CheMastery could be well positioned to take advantage of the opportunity.

The Company’s founders, Dr Anna Andreou and Dr Stefan Glatzel, have deep sector experience and technical credibility. Both were former members of Prof. Leroy Cronin’s globally recognised automated-chemistry research group at the University of Glasgow, and Andreou was a founding team member of its spinout chemistry analysis platform DeepMatter. Described as a “Fitbit for chemistry”, DeepMatter combines in-apparatus sensors with cloud software to record every step of chemical reactions in real time.

CheMastery’s model is highly scalable, with high margins secured on every unit. The Company’s current model achieves a return of £180k ARR per system deployed again a £40k build cost – and management anticipates this to improve further as the Company grows.

The Company has completed three pilots to date – one of which has already converted to a commercial contract worth £180k ARR, expected to be deployed in Q3 2026. The other two pilots have also been successful, and CheMastery is in the process of agreeing contract terms – not guaranteed.

The Company has identified a pipeline worth £800k, which includes pharmaceutical giants such as GSK and several others currently under NDA. The value of the pipeline is based on a single unit per client, and the Company believes it could increase rapidly once capability is proved – not guaranteed.

The round is priced at a £16 million pre-money valuation set by specialist deep-tech investor Kadmos Capital, which is co-leading the round with Blackfinch Ventures (the introducer of this offer). This has been benchmarked against comparable automation and robotics platforms – including RobCo, a next-generation RaaS start-up which members of Kadmos’ team had previously worked on valuing.

The Company is seeking to raise up to £3.5 million under EIS – £2.4 million has already been secured from existing investors, including Blackfinch Ventures and Kadmos Capital. Having already built and validated their MVP (minimum viable product), funds from this raise are expected to be used to support commercial rollout, customer deployment and growth.

Wealth Club has an allocation of up to £500k. The minimum investment is £20,055.45 and you can apply online.

Based on the Company’s forecasts and Co-investors’ assumptions, the target return could be in the region of 14x – high risk and not guaranteed.

As can be expected when investing early stage, the potential rewards are significant, but so are the risks. You should form your own view.

This is a single company offer with no diversification. It involves investing in an early-stage, loss-making business, which is by nature high risk and prone to failure. There is a risk that the capital raised may not be sufficient to achieve the Company’s objectives. You could lose all the amount you invest.

Like all investments available through Wealth Club, it is only for experienced investors happy to make their own investment decisions without advice.

There is no ready market for unlisted EIS shares: they are illiquid and hard to sell and value. There will need to be an exit for you to receive a realised return on your investment. Exits are likely to take considerably longer than the three-year minimum EIS holding period; equally, an exit within three years could impact tax relief.

To claim tax relief, you will need an EIS3 certificate, normally issued once shares have been allotted. This can take several months: please check the deployment timescales carefully. Tax reliefs depend on company maintaining its EIS-qualifying status. Remember, tax rules can change and benefits depend on circumstances. Before you invest, please carefully read the Wealth Club Risks and Commitments.

Investors will invest directly in CheMastery Group Limited. Shares issued in this round are expected to be EIS-qualifying – not guaranteed. Shares are priced at £10.55, equivalent to a pre-money valuation of c.£16 million.

Investors pay an initial charge of 5% deducted from subscription. EIS tax relief will be available on the subscription amount net of the initial charge. Wealth Club will be entitled to a performance fee on exit. Wealth Club investors will invest using a nominee structure. This service is provided by Wealth Club’s subsidiary companies Wealth Club Asset Management Limited (authorised and regulated by the FCA) and Wealth Club Nominees Limited. Wealth Club Nominees Ltd will be completing the share subscription documentation on investors’ behalf.

Please refer to the Schedule of Charges for more details on charges (may vary for different rounds).

All the services Wealth Club and, where applicable, its subsidiaries provide are governed by the Terms and Conditions of the Wealth Club Services.

This financial promotion has been communicated and approved by Wealth Club Ltd on 23 June 2026

Wealth Club aims to make it easier for experienced investors to find information on – and apply for – investments. You should base your investment decision on the offer documents and ensure you have read and fully understand them before investing. The information on this webpage is a marketing communication. It is not advice or a personal or research recommendation to buy any of the investments mentioned, nor does it include any opinion as to the present or future value or price of these investments. It does not satisfy legal requirements promoting investment research independence and is thus not subject to prohibitions on dealing ahead of its dissemination.